Bardoxolone free base

Bardoxolone is a novel nuclear regulator factor activator.

For research use only. Not for human or veterinary use.

Target Keap1-Nrf2 NF-κB SARS-CoV Apoptosis Reactive Oxygen Species (ROS)G lutathione Peroxidase Necroptosis

Research area Infection Neurological Disease Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Bardoxolone structure

CAS No.: 218600-44-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 535.00	BP-01986-1g	In stock	Get quote
2 g	USD 935.00	BP-01986-2g	In stock	Get quote
5 g	USD 1,680.00	BP-01986-5g	In stock	Get quote
10 g	USD 2,680.00	BP-01986-10g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

Bardoxolone is a novel nuclear regulator factor (Nrf-2) activator.

Biological activity

In Vitro Bardoxolone (30 min) reversibly covalently inhibits SARS-CoV-2 3CLpro with an IC50 of 27.99 ± 2.34 μM and a dissociation constant of 25.90 μM. Bardoxolone (48 h) inhibits SARS-CoV-2 replication in Vero and Calu-3 cells with EC50 values of 0.43 and 0.42 μM and selective index of 56.6 and 28.2. Bardoxolone (10-100 nM) induces adipocyte differentiation in 3T3-L1 preadipocytes. Bardoxolone induces differentiation in acute promyelocytic leukemia cell lines (HL-60, NB4, MR2) and primary AML blasts via PPAR-γ-dependent mechanisms, including enhancement of ATRA-induced effects. Bardoxolone induces differentiation in osteosarcoma cells via a PPAR-γ-independent mechanism mediated by caspase-8 activity. Bardoxolone (1-10 μM) exerts antiproliferative and proapoptotic effects in lymphoma and colon cancer cells via inhibition of Lonp1 activity. Bardoxolone (1-10 μM) induces apoptosis in glioblastoma (U87MG, U251MG) and neuroblastoma (SK-N-MC) cell lines. Bardoxolone (1-10 μM) induces intrinsic pathway apoptosis in U-937 leukemia cells with increased ROS and decreased intracellular GSH. Bardoxolone (0.08-10 μM; pre-incubation + 12-16 h) inhibits Z-VAD-FMK-induced necroptosis in HT-29 cells with an EC50 of 1.30 ± 0.38 μM.

Identifiers

SMILES: CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O
InChIKey: TXGZJQLMVSIZEI-UQMAOPSPSA-N

Specifications

MW (average): 491.6615
Formula: C₃₁H₄₁NO₄
CAS No.: 218600-44-3
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO >50mg/mL

Documents

References

[1]. Sun Q, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.

[2]. Borella R, et al. Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids. Molecules. 2019;24(22):4097. Published 2019 Nov 13.

[3]. Wang Y, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2021;212:113030.

Same target

Search Keap1-Nrf2

Same research area

Search Infection